Company Overview and News

MK Land shares surge as investors embrace Perak MB Inc JV news

2018-08-16 theedgemarkets
KUALA LUMPUR (Aug 16): Shares of MK Land Holdings Bhd jumped as much as 17% today, as investors reacted positively to news of its joint venture with Menteri Besar Inc (Perak) (MB Inc) in a proposed mixed development in Perak.

MK Land signs MoU with Perak govt

“The MoU shall remain in effect for a duration of three months from its date, or such longer period as may be agreed by the parties,” MK Land said in a filing with Bursa Malaysia.
BSMAF 8893 1818

Public Bank, Press Metal, KLCCP, CIMB Group, PetChem, PetGas, Sam Engineering, Oriental Interest, Scientex, Mudajaya and MK Land

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): Based on corporate announcements and news flow today, stocks in focus tomorrow may include: Public Bank Bhd, Press Metal Aluminium Holdings Bhd, KLCCP Stapled Group, CIMB Group Holdings Bhd, Petronas Chemicals Group Bhd, Petronas Gas Bhd, Sam Engineering & Equipment (M) Bhd, Oriental Interest Bhd, Scientex Bhd, Mudajaya Group Bhd and MK Land Holdings Bhd.
PBLOF 5183 PECGF 5085 1295 6033 8893 CIMDF 1023 PNADF 8869 5827 PNAGF

MK Land, Perak MB Inc in talks to jointly develop mixed project

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): MK Land Holdings Bhd is teaming up with Menteri Besar Inc (Perak) (MB Inc) to jointly develop a piece of land totalling 226 acres, belonging to the Perak State government, into a mixed development consisting of affordable housing and commercial units.
BSMAF 8893 1818

Trading ideas: Datasonic, Serba Dinamik, MK Land, WZ satu, Vizione

2018-04-16 - 1
KUALA LUMPUR: Datasonic Group Bhd , Serba Dinamik Holdings Bhd, MK Land Holdings Bhd , WZ Satu Bhd and Vizione Holdings Bhd are among the stocks to watch on Monday, according to JF Apex Research.
5216 7245 CSYJY CSYJF 8893 544

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...